Monoclonal antibody prevents #malaria infection in African adults | National Institutes of Health (NIH)
▻https://www.nih.gov/news-events/news-releases/monoclonal-antibody-prevents-malaria-infection-african-adults
One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region. These findings were published today in The New England Journal of Medicine and presented at the American Society of Tropical Medicine & Hygiene 2022 Annual Meeting in Seattle.